CTOs on the Move

Infinity Care Solutions

www.icsrx.com

 
Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.icsrx.com
  • 1204 SE 28th Street Suite 2
    Bentonville, AR USA 72712
  • Phone: 479.250.1443

Executives

Name Title Contact Details
Tom Arens
Vice President of Technology Profile

Similar Companies

JandS Studies

J&S Studies, Inc. is a Bryan, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance Health Networks

Alliance Health Networks is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

genetic Immunity

genetic Immunity is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.